Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 46.25
Bid: 45.50
Ask: 47.00
Change: 1.75 (3.83%)
Spread: 1.50 (3.297%)
Open: 45.75
High: 47.50
Low: 47.50
Prev. Close: 45.75
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

Wed, 14th Jul 2021 11:30

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Symphony Environmental Technologies, up 11% at 21.17 pence, 12-month range 10.65p-47.0p. The anti-microbial plastic technologies firm receives approval from the US Food & Drug Administration for its d2p antimicrobial food contact technology.

----------

88 Energy, up 7.9% at 1.89p, 12-month range 0.24p-4.70p. The Alaska-focused oil exploration and appraisal company says additional phase one geochemical analysis of fluid extracts from Merlin-1 well core samples again demonstrates the presence of hydrocarbons. Results from phase two of side-wall core trim analysis are expected in the next few weeks. Phase two is designed to confirm not only the presence of oil but also the nature of the source rock, to help understand the likely quality of the oil as well as migration pathways.

----------

Alpha FX Group, up 6.7% at 1,665.00p, 12-month range 677p-1,720p. The foreign exchange risk management and international payments firm says trading in the first half ended June 30 has been "strong" across its business, with revenue up 89% year on year at GBP34 million. Adds 84 new clients and notes average revenue per client continued to increase. The company expects to exceed current internal expectations for 2021, on the back of continued strong trading. In 2020, saw revenue of GBP46.2 million with pretax profit of GBP17.1 million.

----------

Avacta, up 5.9% at 143.56p, 12-month range 88.66p-291.80p. The developer of diagnostics and cancer therapies says Life Sciences unit gets ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

----------

Fulcrum Utility Services, up 5.6% at 32.74p, 12-month range 28.25p-43.60p. The energy and multi-utility services provider wins new GBP4.9 million multi-utility infrastructure contract from unnamed "large investor developer", for a "major" new employment park in the West Midlands. As part of the contract, the company will design and install a high voltage primary substation and the electricity, water, and gas infrastructure to "energise and power" the new development.

----------

AIM - LOSERS

----------

Tern, down 13% at 19.40p, 12-month range 5.50p-31.67p. The investment firm completes fundraise at the issue price of 18.8p per share. The retail offer and subscription were both oversubscribed and the company said it raised GBP2 million and GBP4 million, respectively. "We intend to utilise the proceeds to maximise the value to our shareholders of our portfolio, and I look forward to providing further updates in due course," says Chief Executive Al Sisto.

----------

Kromek Group, down 7.0% at 15.00p, 12-month range 7.66p-25.20p. The detection technology firm says revenue totalled GBP10.4 million for the financial year that ended April 30 versus GBP13.1 million the year before. Pretax loss, however, narrows to GBP6.3 million from GBP18.3 million loss the year prior. This is due to non-repeat of GBP13.1 million of exceptional impairment losses on trade receivables and amounts recoverable on contracts. Separately, Kromek says it wins new contracts and orders across all segments for delivery this year.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
4 Aug 2014 08:54

Avacta Group Launches New OPTIM Variants As It seeks new Customers

Read more
1 Aug 2014 10:58

UK MIDDAY BRIEFING: Smith & Nephew Confident In Outlook

Read more
1 Aug 2014 10:36

UK WINNERS & LOSERS: Smith & Nephew, Rexam Lead Few FTSE 100 Risers

Read more
1 Aug 2014 10:33

Friday broker round-up UPDATE

AstraZeneca: Deutsche Bank ups target price from 3950p to 4000p staying with its hold recommendation. Avacta: Numis places both its target price and its buy recommendation under review. Barclays: Berenberg upgrades from sell to hold with a target price of 220p. Bodycote: UBS shifts target price f

Read more
1 Aug 2014 08:22

Avacta Group Falls On Sensipod Delays, North America Problems

Read more
23 Jul 2014 14:17

Sector movers: Weak results, outlook from Glaxo sink pharma stocks

A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a

Read more
15 Jul 2014 10:08

Avacta Appoints Cosmo Bio As Japanese Distributor For Affimers

Read more
4 Jun 2014 09:28

Wednesday broker round-up UPDATE

Advanced Computer Software: Panmure Gordon ups target price from 139p to 155p and stays with its buy recommendation. Avacta: Numis shifts target price from 1.9p to 2p and retains a buy recommendation. Balfour Beatty: Westhouse Securities reduces target price from 302p to 220p keeping its neutral r

Read more
4 Jun 2014 09:07

UK BROKER RATINGS: Morgan Stanley Cuts SABMiller To Equal-Weight

LONDON (Alliance News) - The following UK shares received analyst recommendations Wednesday morning:
----------
FTSE 100
----------
NOMURA RAISES REED ELSEVIER PRICE TARGET TO 1050 (975) PENCE - 'BUY'
----------
CITIGROUP CUTS TULLOW OIL PRICE TA

Read more
2 Jun 2014 09:04

Avacta Gets Funding Award To Support Affirmer Development

LONDON (Alliance News) - Avacta Group PLC Monday said it had secured a funding award from the UK's innovation agency to support it in developing affirmer technology as a potential way of helping develop new cancer treatments. The company is developing affimers, which are engineered alternat

Read more
9 May 2014 10:34

Avacta In Collaboration Deal With UbiQ To Develop Ubiquitin Reagents

LONDON (Alliance News) - Avacta Group PLC Friday said it has signed a collaboration deal with ubiquitylated peptides supplier UbiQ Bio under which the companies will work together to develop reagents that specifically bind to ubiquitin chains. Avacta makes diagnostic tools, consumables and

Read more
9 May 2014 08:30

Avacta collaborates with UbiQ Bio

AIM-listed pharmaceuticals company Avacta Group announced it has signed a collaboration deal with proteins provider UbiQ Bio to build up its chain of ubiquitin Affimers. The group will be providing Avacta with small proteins found in humans and animals to further the firm's development of Affimers

Read more
7 May 2014 10:18

REPEAT: Avacta Raises GBP10.1M In Placing With Additional Option

LONDON (Alliance News) - Avacta Group PLC Wednesday said it has raised GBP10.1 million before expenses through a share placing on 918.2 million shares, which it will use to accelerate the development and commercialisation of Affimers. The shares were placed with both new and existing instit

Read more
7 May 2014 10:16

Avacta Raises GBP10.1M In Share Placing With Additional Option

LONDON (Alliance News) - Avacta Group PLC Wednesday said it has raised GBP10.1 million before expenses through a share placing on 918.2 million shares, which it will use to accelerate the development and commercialisation of Affimers. The shares were placed with both new and existing instit

Read more
23 Apr 2014 12:13

Avacta Loss Narrows, Boosted By Sales Of Analytical Instrument Optim

LONDON (Alliance News) - Avacta Group PLC Wednesday posted a narrowed pretax loss for the year to end-January, boosted by increased sales of its analytical instrument Optim. The biotechnology company posted a pretax loss of GBP500,000, narrowed from GBP807,000 in the previous year, as reven

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.